{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:25:22Z","timestamp":1794925522201,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s13760-023-02367-y","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:02:52Z","timestamp":1693562572000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study"],"prefix":"10.1007","volume":"124","author":[{"given":"Li","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyi","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1909-4898","authenticated-orcid":false,"given":"Weibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"issue":"5","key":"2367_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1055\/s-0036-1586265","volume":"36","author":"DB Drachman","year":"2016","unstructured":"Drachman DB (2016) Myasthenia gravis. Semin Neurol 36(5):419\u2013424. https:\/\/doi.org\/10.1055\/s-0036-1586265","journal-title":"Semin Neurol"},{"issue":"10","key":"2367_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren J (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"5","key":"2367_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/WCO.0000000000000596","volume":"31","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Bernasconi P, Cavalcante P (2018) Myasthenia gravis: from autoantibodies to therapy. Curr Opin Neurol 31(5):517\u2013525. https:\/\/doi.org\/10.1097\/WCO.0000000000000596","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"2367_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ (2018) Treatment of myasthenia gravis. Neurol Clin 36(2):311\u2013337. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.011","journal-title":"Neurol Clin"},{"issue":"8","key":"2367_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF01796261","volume":"44","author":"HM Cherwinski","year":"1995","unstructured":"Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT (1995) Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 44(8):317\u2013322. https:\/\/doi.org\/10.1007\/BF01796261","journal-title":"Inflamm Res"},{"key":"2367_CR6","doi-asserted-by":"publisher","first-page":"107434","DOI":"10.1016\/j.intimp.2021.107434","volume":"93","author":"H Huang","year":"2021","unstructured":"Huang H, Ran H, Liu X, Yu L, Qiu L, Lin Z, Ou C, Lu Y, Yang W, Liu W (2021) Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses. Int Immunopharmacol 93:107434. https:\/\/doi.org\/10.1016\/j.intimp.2021.107434","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2367_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/BOR.0b013e328344fddb","volume":"23","author":"F Behrens","year":"2011","unstructured":"Behrens F, Koehm M, Burkhardt H (2011) Update 2011: leflunomide in rheumatoid arthritis\u2014strengths and weaknesses. Curr Opin Rheumatol 23(3):282\u2013287. https:\/\/doi.org\/10.1097\/BOR.0b013e328344fddb","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"2367_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10067-018-4348-z","volume":"38","author":"M Zhang","year":"2019","unstructured":"Zhang M, Qi C, Zha Y, Chen J, Luo P, Wang L, Sun Z, Wan J, Xing C, Wang S, Jiang G, Sun M, Chen Q, Chen J, Li D, Guan T, Ni Z (2019) Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Clin Rheumatol 38(3):859\u2013867. https:\/\/doi.org\/10.1007\/s10067-018-4348-z","journal-title":"Clin Rheumatol"},{"issue":"11","key":"2367_CR9","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s11255-019-02255-6","volume":"51","author":"J Yi","year":"2019","unstructured":"Yi J, He Z, Xu S, Feng S (2019) Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis. Int Urol Nephrol 51(11):1987\u20131998. https:\/\/doi.org\/10.1007\/s11255-019-02255-6","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"2367_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0192-0561(95)00009-q","volume":"17","author":"B Vidic-Dankovic","year":"1995","unstructured":"Vidic-Dankovic B, Kosec D, Damjanovic M, Apostolski S, Isakovic K, Bartlett RR (1995) Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 17(4):273\u2013281. https:\/\/doi.org\/10.1016\/0192-0561(95)00009-q","journal-title":"Int J Immunopharmacol"},{"issue":"1","key":"2367_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00415-015-7944-8","volume":"263","author":"P Chen","year":"2016","unstructured":"Chen P, Feng H, Deng J, Luo Y, Qiu L, Ou C, Liu W (2016) Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. J Neurol 263(1):83\u201388. https:\/\/doi.org\/10.1007\/s00415-015-7944-8","journal-title":"J Neurol"},{"key":"2367_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13760-021-01769-0","volume":"123","author":"X Huang","year":"2021","unstructured":"Huang X, Qiu L, Lu Y, Chen J, Yang W, Ou C, Ran H, Liu W (2021) Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis. Acta Neurol Belg 123:153\u2013160. https:\/\/doi.org\/10.1007\/s13760-021-01769-0","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"2367_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","volume":"45","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Burns TM et al (2012) Recommendations for myasthenia gravis clinical trials. Muscle Nerve 45(6):909\u2013917. https:\/\/doi.org\/10.1002\/mus.23330","journal-title":"Muscle Nerve"},{"issue":"9","key":"2367_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/jnnp.2011.243931","volume":"82","author":"M Benatar","year":"2011","unstructured":"Benatar M, Sanders D (2011) The importance of studying history: lessons learnt from a trial of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 82(9):945. https:\/\/doi.org\/10.1136\/jnnp.2011.243931","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2367_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1196\/annals.1405.031","volume":"1132","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Siddiqi ZA (2008) Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann N Y Acad Sci 1132:249\u2013253. https:\/\/doi.org\/10.1196\/annals.1405.031","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2367_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s0003-4975(00)01595-2","volume":"70","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 70(1):327\u2013334. https:\/\/doi.org\/10.1016\/s0003-4975(00)01595-2","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"2367_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4049\/jimmunol.0802046","volume":"183","author":"C Luther","year":"2009","unstructured":"Luther C, Adamopoulou E, Stoeckle C, Brucklacher-Waldert V, Rosenkranz D, Stoltze L, Lauer S, Poeschel S, Melms A, Tolosa E (2009) Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J Immunol 183(2):841\u2013848. https:\/\/doi.org\/10.4049\/jimmunol.0802046","journal-title":"J Immunol"},{"issue":"1","key":"2367_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ncl.2020.09.007","volume":"39","author":"C Bodkin","year":"2021","unstructured":"Bodkin C, Pascuzzi RM (2021) Update in the management of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Neurol Clin 39(1):133\u2013146. https:\/\/doi.org\/10.1016\/j.ncl.2020.09.007","journal-title":"Neurol Clin"},{"issue":"12","key":"2367_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316(12):719\u2013724. https:\/\/doi.org\/10.1056\/NEJM198703193161205","journal-title":"N Engl J Med"},{"issue":"11","key":"2367_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/jnnp.56.11.1157","volume":"56","author":"Myasthenia Gravis Clinical Study Group","year":"1993","unstructured":"Myasthenia Gravis Clinical Study Group (1993) A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry 56(11):1157\u20131163. https:\/\/doi.org\/10.1136\/jnnp.56.11.1157","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2367_CR21","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/wnl.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50(6):1778\u20131783. https:\/\/doi.org\/10.1212\/wnl.50.6.1778","journal-title":"Neurology"},{"issue":"6","key":"2367_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71(6):400\u2013406. https:\/\/doi.org\/10.1212\/01.wnl.0000312374.95186.cc","journal-title":"Neurology"},{"issue":"9","key":"2367_CR23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","volume":"82","author":"H Yoshikawa","year":"2011","unstructured":"Yoshikawa H, Kiuchi T, Saida T, Takamori M (2011) Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 82(9):970\u2013977. https:\/\/doi.org\/10.1136\/jnnp-2011-300148","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"2367_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","volume":"10","author":"L Zhou","year":"2017","unstructured":"Zhou L, Liu W, Li W, Li H, Zhang X, Shang H, Zhang X, Bu B, Deng H, Fang Q, Li J, Zhang H, Song Z, Ou C, Yan C, Liu T, Zhou H, Bao J, Lu J, Shi H, Zhao C (2017) Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. Ther Adv Neurol Disord 10(9):315\u2013325. https:\/\/doi.org\/10.1177\/1756285617721092","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"2367_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4):419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"issue":"3","key":"2367_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"issue":"11","key":"2367_CR27","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, H\u00e5kansson I, Johansson R, Jons D, Kmezic I, Lindberg C, Lindh J, Lundin F, Nygren I, Punga AR, Press R, Samuelsson K, Sundstr\u00f6m P, Wickberg O, Brauner S, Frisell T (2022) Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol 79(11):1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"issue":"12","key":"2367_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O\u2019Brien F, Wang JJ, Mantegazza R, REGAIN Study Group (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"issue":"5","key":"2367_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","volume":"93","author":"C Nelke","year":"2022","unstructured":"Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, Arat E, \u00d6zt\u00fcrk M, Melzer N, Mergenthaler P, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Schreiber S, Vielhaber S, Hartung HP, Meisel A, Wiendl H, Meuth SG, Ruck T (2022) Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry 93(5):548\u2013554. https:\/\/doi.org\/10.1136\/jnnp-2021-328665","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"2367_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R, ADAPT Investigator Study Group (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"issue":"6","key":"2367_CR31","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"V Bril","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, Kiessling P, Woltering F, Griffin L, Van den Bergh P, MG0002 Investigators (2021) Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology 96(6):e853\u2013e865. https:\/\/doi.org\/10.1212\/WNL.0000000000011108","journal-title":"Neurology"},{"issue":"5","key":"2367_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, \u015ami\u0142owski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI, RAISE Study Team (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22(5):395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"issue":"4","key":"2367_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C (2020) Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry 91(4):392\u2013395. https:\/\/doi.org\/10.1136\/jnnp-2019-322606","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2367_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","volume":"48","author":"A Nacu","year":"2015","unstructured":"Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE (2015) Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity 48(6):362\u2013368. https:\/\/doi.org\/10.3109\/08916934.2015.1030614","journal-title":"Autoimmunity"},{"issue":"4","key":"2367_CR35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10067-022-06062-w","volume":"41","author":"R Bixio","year":"2022","unstructured":"Bixio R, Bertelle D, Pistillo F, Pedrollo E, Carletto A, Rossini M, Viapiana O (2022) Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options. Clin Rheumatol 41(4):1247\u20131254. https:\/\/doi.org\/10.1007\/s10067-022-06062-w","journal-title":"Clin Rheumatol"},{"issue":"4","key":"2367_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1517\/14740338.2013.798299","volume":"12","author":"HI Keen","year":"2013","unstructured":"Keen HI, Conaghan PG, Tett SE (2013) Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin Drug Saf 12(4):581\u2013588. https:\/\/doi.org\/10.1517\/14740338.2013.798299","journal-title":"Expert Opin Drug Saf"},{"key":"2367_CR37","doi-asserted-by":"publisher","first-page":"961628","DOI":"10.3389\/fneur.2022.961628","volume":"13","author":"X Huang","year":"2022","unstructured":"Huang X, Ran H, Li Y, Ma Q, Ou C, Qiu L, Feng H, Liu W (2022) Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients. Front Neurol 13:961628. https:\/\/doi.org\/10.3389\/fneur.2022.961628","journal-title":"Front Neurol"},{"issue":"5\u20136","key":"2367_CR38","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A (2010) Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43(5\u20136):428\u2013435. https:\/\/doi.org\/10.3109\/08916930903518107","journal-title":"Autoimmunity"},{"issue":"2","key":"2367_CR39","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/neurolint14020033","volume":"14","author":"A Lupica","year":"2022","unstructured":"Lupica A, Di Stefano V, Iacono S, Pignolo A, Quartana M, Gagliardo A, Fierro B, Brighina F (2022) Impact of COVID-19 in AChR myasthenia gravis and the safety of vaccines: data from an italian cohort. Neurol Int 14(2):406\u2013416. https:\/\/doi.org\/10.3390\/neurolint14020033","journal-title":"Neurol Int"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02367-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-023-02367-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02367-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T16:08:19Z","timestamp":1708186099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-023-02367-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2367"],"URL":"https:\/\/doi.org\/10.1007\/s13760-023-02367-y","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of the first affiliated hospital of Sun Yat-sen University (2012\u2013296).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}